Sandrine Macé

4.2k total citations
88 papers, 1.4k citations indexed

About

Sandrine Macé is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sandrine Macé has authored 88 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 39 papers in Oncology and 34 papers in Molecular Biology. Recurrent topics in Sandrine Macé's work include Multiple Myeloma Research and Treatments (53 papers), Peptidase Inhibition and Analysis (23 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Sandrine Macé is often cited by papers focused on Multiple Myeloma Research and Treatments (53 papers), Peptidase Inhibition and Analysis (23 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Sandrine Macé collaborates with scholars based in France, United States and United Kingdom. Sandrine Macé's co-authors include Scott A. Neslin, Emmanuelle Cousin, Jean‐François Deleuze, Sylvain Ricard, Mark A. Dickson, Andrew J. Wagner, Philippe Moreau, Axel Le Cesne, Emmanuelle Génin and Alexis Brice and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sandrine Macé

85 papers receiving 1.4k citations

Peers

Countries citing papers authored by Sandrine Macé

Since Specialization

Citations

This map shows the geographic impact of Sandrine Macé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Macé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Macé more than expected).

Fields of papers citing papers by Sandrine Macé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Macé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Macé. The network helps show where Sandrine Macé may publish in the future.

Co-authorship network of co-authors of Sandrine Macé

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Macé. A scholar is included among the top collaborators of Sandrine Macé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Macé. Sandrine Macé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials 2025 ·Annals of Hematology ·Meletios Α. Dimopoulos, Kazutaka Sunami, Xavier Leleu, Ravi Vij, Cristina Gasparetto, Kenshi Suzuki, Sandrine Macé, (unknown), (unknown), Shinsuke Iida	1
2	Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients 2025 ·Blood ·Enrique M. Ocio, Aurore Perrot, Jesús F. San Miguel, Lionel Karlin, Joaquín Martínez‐López, (unknown), Paula Rodríguez‐Otero, Mohamad Mohty, (unknown), Meletios Α. Dimopoulos, Xavier Leleu, María‐Victoria Mateos, Philippe Moreau, Sandrine Macé, Ercem Kodas, Christina Tekle, (unknown), Corina Oprea, Thierry Façon	0
3	A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma 2024 ·Haematologica ·Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothée Sémiond, (unknown), Paúl Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau	2
4	Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma 2024 ·The Journal of Applied Laboratory Medicine ·Katie Thoren, (unknown), (unknown), Sandrine Macé	3
5	Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). 2024 ·Journal of Clinical Oncology ·Thierry Façon, Meletios Α. Dimopoulos, Xavier Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Špıčka, Vladimir Vorobyev, Michèle Cavo, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, (unknown), Sandrine Macé, (unknown), Robert Z. Orlowski	3
6	An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma 2024 ·European Journal Of Haematology ·Prashant Kapoor, Nitya Nathwani, Tomáš Jelı́nek, Luděk Pour, Aurore Perrot, Meletios Α. Dimopoulos, Shang‐Yi Huang, Ivan Špıčka, Saurabh Chhabra, Eben I. Lichtman, María‐Victoria Mateos, (unknown), Liang Zhao, (unknown), Sandrine Macé, Helgi van de Velde, Paul G. Richardson	1
7	Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies 2024 ·Blood Cancer Journal ·Paul G. Richardson, Aurore Perrot, Joseph Mıkhael, Thomas G. Martin, Meral Beksaç, Ivan Špıčka, Marcelo Capra, Mattia D’Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, (unknown), Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau	3
8	Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study 2024 ·Hematological Oncology ·Thierry Façon, Philippe Moreau, Ivan Špıčka, Kenshi Suzuki, Kwee Yong, Joseph Mıkhael, Taro Fukao, Kamlesh Bisht, Nicole D. Armstrong, Sandrine Macé, Marie‐Laure Risse, Thomas G. Martin	6
9	Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study 2024 ·Blood ·Enrique M. Ocio, Aurore Perrot, Pierre Bories, Jesús F. San Miguel, Lionel Karlin, Joaquín Martínez‐López, (unknown), (unknown), María‐Victoria Mateos, Paula Rodríguez‐Otero, Stefania Oliva, Axel Nogai, Bruno Paiva, Yi Li, (unknown), Sandrine Macé, Ercem Kodas, Helgi van de Velde, Philippe Moreau	1
10	Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis 2024 ·Haematologica ·Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios Α. Dimopoulos, Shang‐Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, (unknown), Kenneth C. Anderson	4
11	P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES 2023 ·HemaSphere ·Aurore Perrot, Paul G. Richardson, Joseph Mıkhael, Thomas G. Martin, Meral Beksaç, Ivan Špıčka, Marcelo Capra, Mattia D’Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, (unknown), Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau	1
12	A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma 2023 ·Clinica Chimica Acta ·(unknown), Christophe Hirtz, (unknown), Olivier Fedeli, Sandrine Macé, Sylvain Lehmann, Jérôme Vialaret	3
13	Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients from Clinical Trial NCT02513186 2023 ·Blood ·(unknown), (unknown), (unknown), (unknown), Sandrine Macé, Zandra Klippel, Vincent Bonifay, (unknown), P. Sonigo	1
14	Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics 2021 ·British Journal of Haematology ·Simon J. Harrison, Aurore Perrot, Adrían Alegre, David Simpson, (unknown), Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Façon, Philip Vlummens, Kwee Yong, Frank Campana, (unknown), Sandrine Macé, Marie‐Laure Risse, Helgi van de Velde, Paul G. Richardson	32
15	614P Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance 2021 ·Annals of Oncology ·Johann S. de Bono, Klaus Pantel, Eleni Efstathiou, Cora N. Sternberg, D. Castellano Gauna, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Joseph D. Schonhoft, (unknown), (unknown), (unknown), Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Sandrine Macé, Ronald de Wit	2
16	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis 2020 ·Blood ·Thomas G. Martin, Joseph Mıkhael, Roman Hájek, Kihyun Kım, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, (unknown), Т. С. Константинова, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau	12
17	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma 2016 ·Nature Communications ·Joonil Jung, Joon Sang Lee, Mark A. Dickson, Gary K. Schwartz, Axel Le Cesne, Andréa Varga, Rastilav Bahleda, Andrew J. Wagner, Edwin Choy, Maja J. De Jonge, (unknown), (unknown), Sandrine Macé, James Watters	78
18	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor 2015 ·Breast Cancer Research and Treatment ·Kimberly Blackwell, Howard A. Burris, Patricia Gómez, N. Lynn Henry, Steven J. Isakoff, Frank Campana, Lei Gao, Jason Jiang, Sandrine Macé, Sara M. Tolaney	30
19	A risk for early-onset Alzheimer's disease associated with the APBB1 gene (FE65) intron 13 polymorphism 2003 ·Neuroscience Letters ·Emmanuelle Cousin, Didier Hannequin, Sylvain Ricard, Sandrine Macé, Emmanuelle Génin, (unknown), Alexis Brice, Bruno Dubois, Thierry Frébourg, Luc Mercken, Jesús Bénavidès, Laurent Pradier, Dominique Campion, Jean‐François Deleuze	12
20	Association Studies in Candidate Genes: Strategies to Select SNPs to Be Tested 2003 ·Human Heredity ·Emmanuelle Cousin, Emmanuelle Génin, Sandrine Macé, Sylvain Ricard, (unknown), Maria Del Zompo, (unknown)	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact